EGFR and non-small cell lung carcinoma: Chemotherapy and EGFR‐TKI treatment resulted in significantly longer PFS in patients with EGFR‐positive NSCLC (HR = 0.68, 95% CI: 0.51–0.89, p = 0.005) (Figure S2A, Table S1).